Morningside Healthcare is dedicated to providing quality products without compromise.
Our headline brands highlight our ability to bring bioequivalent products to the NHS, which has resulted in significant cost saving opportunities for CCG’s.
These benefits are in line with stated government policy to increase efficiencies in the NHS.
All our headline brands are widely available through mainline pharmaceutical wholesalers, and we ensure that sufficient stock levels are available to meet anticipated demands.
At Morningside Healthcare we are proud to provide our NHS partners with:
- Bioequivalent products with significant cost saving opportunities
- Reassurance of supply continuity
- Dedicated patient and healthcare professional websites for advice and support
- Free patient advice leaflets and template letters for prescribers
Summary of Product Characteristics (SmPC) for products listed below can be found here
In reference to Morningside Healthcare’s oral contraceptives (Levest®, Cimizt®, Lizinna® and Zelleta®), Dr Farook Al-Azzawi. Consultant Gynaecologist at Leicester Royal Infirmary said:
“
This is a wonderful – and rare – opportunity for CCGs to make impressive cost savings. It is not often that we have a chance to easily cut costs, and here we have it.
By simply changing the name of the drug and informing the patient that it is exactly the same contraceptive pill containing the same active ingredients, but with different name, packaging and manufacturer, we have the opportunity to save.
This process is so much easier than changing entire therapies, and then having consequent reviews and potential side effects to deal with. We can keep the treatment the same but a simple change to a branded generic can make vital financial savings across CCGs.
”
Dr Farook Al-Azzawi. Consultant Gynaecologist at Leicester Royal Infirmary
Bimizza
Desogestrel 150mcg/ Ethinylestradiol 20mcg
|
Strength |
150mcg/20mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
63 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
150mcg/20mcg |
Tablets |
63 |
SmPC |
|
|
Patient Leaflet |
|
|
Cimizt
Desogestrel 150mcg/ Ethinylestradiol 30mcg
|
Strength |
150mcg/30mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
63 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
150mcg/30mcg |
Tablets |
63 |
SmPC |
|
|
Patient Leaflet |
|
|
Emerres
Levonorgestrel 1500mcg
|
Strength |
1500mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
1 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|||
|
Risk Materials |
|
|||
|
Letters to HCPs |
|
|
Strength |
Form |
Pack Size |
|
1500mcg |
Tablets |
1 |
|
SmPC |
|
|
|
Patient Leaflet |
|
|
|
Risk Materials |
|
|
|
Letters to HCPs |
|
Hylaton
Chlortalidone
|
Strength |
12.5mg |
50mg |
||
|
Form |
Tablets |
Tablets |
||
|
Pack Size |
30 |
30 |
||
|
SmPC |
|
|
||
|
Patient Leaflet |
|
|
|
Strength |
Form |
Pack Size |
|
12.5mg |
Capsules |
30 |
|
SmPC |
|
|
|
Patient Leaflet |
|
|
|
50mg |
Capsules |
30 |
|
SmPC |
|
|
|
Patient Leaflet |
|
Ixyldone
Oxycodone hydrochloride
5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg
|
Strength |
5mg |
10mg |
15mg |
20mg |
30mg |
40mg |
60mg |
80mg |
|
Form |
Tablets |
Tablets |
Tablets |
Tablets |
Tablets |
Tablets |
Tablets |
Tablets |
|
Pack Size |
28 |
56 |
56 |
56 |
56 |
56 |
56 |
56 |
|
SmPC |
|
|
|
|
|
|
|
|
|
Patient Leaflet |
|
|
|
|
|
|
|
|
|
Strength |
Form |
Pack Size |
|
5mg |
Tablets |
28 |
SmPC |
|
|
Patient Leaflet |
|
|
|
10mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
15mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
20mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
30mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
40mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
60mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
80mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
Levest
Levonorgestrel 150mcg/ Ethinylestradiol 30mcg
|
Strength |
150mcg/30mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
63 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
150mcg/30mcg |
Tablets |
63 |
SmPC |
|
|
Patient Leaflet |
|
|
Lizinna
Norgestimate 250mcg/ Ethinylestradiol 35mcg
|
Strength |
250mcg/35mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
63 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
250mcg/35mcg |
Tablets |
63 |
SmPC |
|
|
Patient Leaflet |
|
|
Sukkarto SR
Metformin Hydrochloride Prolonged Release
|
Strength |
500mg |
750mg |
1000mg |
|
|
Form |
Tablets |
Tablets |
Tablets |
|
|
Pack Size |
56 |
56 |
56 |
|
|
SmPC |
|
|
|
|
|
Patient Leaflet |
|
|
|
|
Strength |
Form |
Pack Size |
|
500mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
750mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
|
1000mg |
Tablets |
56 |
SmPC |
|
|
Patient Leaflet |
|
|
Vensir XL
Venlafaxine Hydrochloride Prolonged Release
|
Strength |
75mg |
150mg |
225mg |
|
|
Form |
Capsules |
Capsules |
Capsules |
|
|
Pack Size |
28 |
28 |
28 |
|
|
SmPC |
|
|
|
|
|
Patient Leaflet |
|
|
|
|
Strength |
Form |
Pack Size |
|
75mg |
Capsules |
28 |
SmPC |
|
|
Patient Leaflet |
|
|
|
150mg |
Capsules |
28 |
SmPC |
|
|
Patient Leaflet |
|
|
|
225mg |
Capsules |
28 |
SmPC |
|
|
Patient Leaflet |
|
|
Yacella
Ethinylestradiol 0.03mg / Drospirenone 3mg
|
Strength |
0.03mg/3mg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
63 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|||
|
Risk Materials |
|
Letters to HCPs |
|
|
Strength |
Form |
Pack Size |
|
0.03mg/3mg |
Tablets |
63 |
SmPC |
|
|
Patient Leaflet |
|
|
Risk Materials |
|
|
Letters to HCPs |
|
Zelleta
Desogestrel 75mcg
|
Strength |
75mcg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
84 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
75mcg |
Tablets |
84 |
SmPC |
|
|
Patient Leaflet |
|
|
Zintasa
Mesalazine
|
Strength |
400mg |
|||
|
Form |
Tablets |
|||
|
Pack Size |
120 |
|||
|
SmPC |
|
|||
|
Patient Leaflet |
|
|
Strength |
Form |
Pack Size |
|
400mg |
Tablets |
120 |
SmPC |
|
|
Patient Leaflet |
|
|
“
It makes absolute sense to switch to branded generic products such as Levest®, Cimizt®, Lizinna® and Zelleta®, as patients are receiving the medication they require with an equivalent brand where switching is therapeutically neutral, but at a fraction of the price. This really helps us to take some of the financial pressures off the surgery’s prescribing budget.
”